ReviewFrontiers in immunology2026
Pathological networks and multi-target interventions in sepsis-associated acute lung injury: from pathogen-host interactions to gut-lung axis regulation.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Sepsis is a life-threatening organ dysfunction resulting from a dysregulated host response to infection, accounting for an estimated 11 million deaths annually worldwide. Among its most prevalent and severe complications is acute respiratory distress syndrome (ARDS). Traditional research has focused on isolated pathways such as inflammation and oxidative stress; however, the results of clinical trials for related targeted drugs have been less than ideal. The core reason is that sepsis-associated acute lung injury (SA-ALI) is not driven by a single, independent pathway, but rather by an interconnected pathological network activated jointly by pathogen-associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs), featuring multiple positive feedback loops. In this network, pathogen virulence factors serve as upstream initiation nodes, while mitochondrial dysfunction acts as a central regulatory hub. Downstream, four major effect modules-immune and inflammatory dysregulation, oxidative stress and coagulation imbalance, bidirectional disruption of the gut-lung axis, and ferroptosis-are linked in series. Multiple links in this network synergistically amplify damage to alveolar epithelium and endothelium, ultimately leading to diffuse pulmonary edema, gas exchange failure, and multi-organ failure. Methods: This paper systematically searched PubMed, Web of Science, and CNKI databases from 2000 to 2026, using the search terms "sepsis, acute lung injury, ferroptosis, gut-lung axis, phage therapy, and mitochondrial-targeted interventions." We screened for literature on fundamental mechanisms, animal studies, clinical cohort studies, and reviews, while excluding low-relevance studies based solely on Results: 1. The virulence pathways of different bacteria, fungi, and viruses exhibit a pattern of "heterogeneous triggering and downstream convergence," with damage signals from various pathogens ultimately converging at two core network hubs: mitochondrial dysfunction and ferroptosis; 2. There are multilevel positive feedback loops among immune and inflammatory dysregulation, oxidative stress, coagulation disorders, the gut-lung axis, and ferroptosis; blocking a single pathway is offset by compensatory pathways within the network, which explains the clinical failure of single-target drugs; 3. Existing interventions can be classified into five major categories: upstream anti-infection, midstream mitochondrial protection, downstream inhibition of inflammation/ferroptosis, epigenetic regulation, and natural small-molecule adjuvants. Each therapeutic approach has well-defined synergistic targets, and their combined use can simultaneously block multiple damage nodes within the network; 4. The source of infection, age, immune status, and underlying comorbidities reshape the topological structure of the pathological network, leading to heterogeneity in treatment response and necessitating stratified, individualized interventions. Discussion: This review overcomes the limitations of traditional reviews-which often present "fragmented discussions focused on a single pathway"-by using an interconnected pathological network as the central thread to link all content throughout. It innovatively proposes a three-tiered network regulation theory; systematically compares the development stages, clinical bottlenecks, and synergistic value of various therapies; and provides a comprehensive theoretical framework for precision stratified treatment of SA-ALI and the identification of new drug targets. Targeting central network nodes such as mitochondria and employing phased, sequential multi-target combination regimens offer superior lung-protective effects compared to single-pathway inhibitors and represent a core research direction for improving the long-term prognosis of patients with sepsis complicated by ARDS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.